TY - JOUR

T1 - СВЯЗЬ УРОВНЯ ФЕКАЛЬНОГО ЗОНУЛИНА И КАЛЬПРОТЕКТИНА С ФАКТОРАМИ СЕРДЕЧНО-СОСУДИСТОГО РИСКА И ПОРАЖЕНИЕМ ОРГАНОВ-МИШЕНЕЙ В ВЫБОРКЕ ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМИ НАРУШЕНИЯМИ

AU - Колесова, Екатерина

AU - Маслянский, Алексей Леонидович

AU - Усольцев, Дмитрий

AU - Могучая, Екатерина

AU - Бояринова, Мария

AU - Ерина, Анастасия

AU - Толкунова, Кристина

AU - Мазинг, Александра

AU - Кибкало, София

AU - Васильева, Елена

AU - Новикова, Наталья

AU - Ермоленко, Елена

AU - Артемов, Никита

AU - Ротарь, Оксана

AU - Конради, Александра

AU - Шляхто, Е. В.

PY - 2023/10/21

Y1 - 2023/10/21

N2 - Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered non-traditional cardiovascular risk factors. Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years. Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out. Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ≥1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns. Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.

AB - Surrogate markers quantifying the severity of intestinal inflammation (fecal calprotectin) and permeability (fecal zonulin) are currently considered non-traditional cardiovascular risk factors. Aim. To study the associations of fecal zonulin and calprotectin levels with cardiovascular risk factors and target organ damage among participants with metabolic disorders from a population sample of St. Petersburg residents aged 35-75 years. Material and methods. In-depth phenotyping was performed on patients from a cohort of St. Petersburg residents metabolic disorders (overweight, hyperglycemia) invited for reexamination as part of the ESSE-RF epidemiological study. All patients underwent a questionnaire examination (physical activity, smoking, alcohol consumption, sleep, stress, anxiety and depression, assessment of digestive system complaints, frequency of food consumption). In addition, blood pressure and pulse measurements, anthropometry, biochemical and hormonal blood tests, echocardiography, applanation tonometry, volume sphygmography, duplex carotid scanning, and determination of fecal zonulin and calprotectin levels were carried out. Results. The examined cohort (n=86; mean age, 56 [44,7;63,5] years; men, 49,5%) was characterized by a high prevalence of abdominal obesity (80,2%), dyslipidemia (low-density lipoproteins >3 mmol/l — 76,7%, triglycerides ≥1,7 mmol/l — 43%, total cholesterol >4,9 mmol/l — 77,9%) and insulin resistance (64%) with slight sex differences. An increase in calprotectin occurs in 23,3% of patients, zonulin — in 30,3%, while an increase in calprotectin and/or zonulin occurs in almost half of those examined (47,7%). Fecal calprotectin levels are associated with indicators of dyslipidemia, obesity, inflammation and atherosclerotic vascular disease, as well as dietary patterns and socioeconomic indicators. Zonulin levels are associated with N-terminal probrain natriuretic peptide levels and the presence of vitamin D deficiency, gallbladder disease, and dietary patterns. Conclusion. Increase of at least one marker of intestinal permeability and inflammation occur in approximately half of the participants with metabolic disorders from a population sample of St. Petersburg residents. In addition to the association of calprotectin and zonulin with metabolic risk factors and dietary patterns, calprotectin levels were associated with atherosclerotic changes in the carotid arteries.

KW - calprotectin

KW - metabolic disorders

KW - target organ damage

KW - zonulin

UR - https://www.mendeley.com/catalogue/187e68d0-a4b8-3f0b-9008-bd66044c8751/

U2 - 10.15829/1560-4071-2023-5569

DO - 10.15829/1560-4071-2023-5569

M3 - статья

VL - 28

SP - 108

EP - 118

JO - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

JF - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

SN - 1560-4071

IS - 11

ER -